e-learning
resources
Vienna 2003
Tuesday 30.09.2003
The challenge of community acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pneumococcal pneumonia in hospitalized patients. Therapeutic implications of resistances to penicillin and erythromycin
Source:
Annual Congress 2003 - The challenge of community acquired pneumonia
Session:
The challenge of community acquired pneumonia
Session type:
Poster Discussion
Number:
3393
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Pneumococcal pneumonia in hospitalized patients. Therapeutic implications of resistances to penicillin and erythromycin. Eur Respir J 2003; 22: Suppl. 45, 3393
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Evolution of antimicrobial resistance trends in the last five years in patients with bacteremic Pneumococcal community-acquired pneumonia (CAP-SP)
Source: Eur Respir J 2005; 26: Suppl. 49, 639s
Year: 2005
Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Fluoroquinolone
versus
β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 53s
Year: 2007
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Pneumococcal pneumonia: an old disease with radically-new approaches for antibiotic therapy
Source: Annual Congress 2005 - Outcome in severe pneumonia
Year: 2005
Etiology and antibiotic resistance patterns in adults with severe community-acquired pneumonia in Russia
Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment
Year: 2019
Treatment of nosocomial pneumonia with piperacillin-tazobactam
Source: Eur Respir J 2007; 30: Suppl. 51, 53s
Year: 2007
Antibiotic management of nosocomial pneumonia in children
Source: Eur Respir J 2006; 28: Suppl. 50, 633s
Year: 2006
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections
Source: Eur Respir J 2002; 20: 3S-8S
Year: 2002
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Antibiotic resistance and nosocomial pneumonia
Source: Eur Respir J 2005; 26: Suppl. 49, 641s
Year: 2005
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014
Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept